Amyotrophic lateral sclerosis (ALS) is a challenging disease characterized by progressive loss of motor neurons. This is manifested in deterioration of strength, gait, speech, swallowing, respiratory function, and eventually leads to death. A major hurdle in development of effective therapy is rooted ...
Fig. 1 |NeuroNata-R is a stem cell therapy approved in South Korea for ALS.NeuroNata-R has various effects that prevent motor neuron death and slow disease progression in patients with amyotrophic lateral sclerosis (ALS)1,2,3. BDNF, brain-derived neurotrophic factor; TH2, T helper 2; Tre...
Stem Cells as a Treatment for Chronic Liver Disease and Diabetes Advances in stem cell biology and the discovery of pluripotent stem cells have made the prospect of cell therapy and tissue regeneration a clinical reality... N Levicar,I Dimarakis,C Flores,... - 《Handb Exp Pharmacol》 被引...
Amyotrophic lateral sclerosis (ALS) is a challenging disease characterized by progressive loss of motor neurons. This is manifested in deterioration of strength, gait, speech, swallowing, respiratory function, and eventually leads to death. A major hurdle in development of effective therapy is rooted ...
There is currently no treatment or cure for ALS, also known as Lou Gehrig's disease. Several hospitals across the U.S. are testing a new stem cell therapy that doctors and patients hope will help. Dr. Mallika Marshall reports from Boston.
Stem cell therapy for Parkinson’s offers numerous advantages that include: Improved movement; Protection from neurodegeneration, which is characteristic of Parkinson’s disease; Slow down the progression of the disease; Reducing inflammation; Boosting neurogenesis; ...
committee meetingit asked for but not the outcome it wanted. After a full day of presentations and testimonials, the panel of outside experts on Wednesday evening voted against recommending regulatory approval of the company’s experimental stem cell therapy for amyotrophic lateral sclerosis, or ALS...
Injury and disease of the spinal cord are generally met with a poor prognosis. This poor prognosis is due not only to the characteristics of the diseases but also to our poor ability to deliver therapeutics to the spinal cord. The spinal cord is extremel
Parkinson's disease is a common neurodegenerative disease with a lifetime incidence of 2.5% and a prevalence of at least 2% in individuals over 70 years ol... SE Lazic,RA Barker - 《Journal of Hematotherapy & Stem Cell Research》 被引量: 52发表: 2003年 Cell-based therapies for Parkinson...
a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig's disease. ...